title: Caspofungin in the treatment of symptomatic candiduria.
abstract: BACKGROUND
  Because the urine concentrations achieved by echinocandin antifungal agents are low, drugs from this class are excluded from consideration when candiduria treatment is selected.
  
  
  METHODS
  We performed a retrospective view (sponsored by Merck Research Laboratories) of case records of patients participating in phase II-III clinical studies of caspofungin to identify patients with candiduria.
  
  
  RESULTS
  Of 12 case records collected by Merck Research Laboratories, 6 met the criteria for significant candiduria, allowing the evaluation of caspofungin therapy as judged by J.D.S. Three reported cases of candiduria secondary to hematogenous renal candidiasis were promptly eradicated. Of greater significance are 3 cases of complicated, ascending Candida glabrata infection (i.e., C. glabrata infection plus renal insufficiency), which were successfully treated with caspofungin.
  
  
  CONCLUSIONS
  Caspofungin may have a role in treating complicated Candida urinary tract infections, especially when the infection is caused by non-albicans species of Candida.
authors.affiliation: Department of Medicine, Wayne State University School of Medicine, Detroit, MI, USA. jsobel@med.wayne.edu
authors.forename: Jack D
authors.initials: JD
authors.lastname: Sobel
authors.forename: Susan K
authors.initials: SK
authors.lastname: Bradshaw
authors.forename: C Joy
authors.initials: CJ
authors.lastname: Lipka
authors.forename: Nicholas A
authors.initials: NA
authors.lastname: Kartsonis
mesh_terms: D000368:Aged; D000892:Anti-Infective Agents, Urinary / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000627:therapeutic use*; D001437:Bacteriuria / Q000175:diagnosis / Q000188:drug therapy*; D002175:Candida / Q000187:drug effects; D002177:Candidiasis / Q000175:diagnosis / Q000188:drug therapy* / Q000652:urine; D000077336:Caspofungin; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D054714:Echinocandins; D005260:Female; D006801:Humans; D055666:Lipopeptides; D008297:Male; D008875:Middle Aged; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D012189:Retrospective Studies
chemical_list: D000892:Anti-Infective Agents, Urinary; D000935:Antifungal Agents; D054714:Echinocandins; D055666:Lipopeptides; D010456:Peptides, Cyclic; D000077336:Caspofungin